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ABSTRACT
Myelodysplastic syndromes (MDS) are stem cell disorders caused by various 
gene abnormalities. We performed targeted deep sequencing in 39 patients with 
high-risk MDS and secondary acute myeloid leukemia (sAML) at diagnosis and follow-
up (response and/or relapse), with the aim to define their mutational status, to 
establish if specific mutations are biomarkers of response to 5-azacytidine (AZA) 
and/or may have impact on survival. Overall, 95% of patients harbored at least 
one mutation. TP53, DNMT3A and SRSF2 were the most frequently altered genes. 
Mutations in TP53 correlated with higher risk features and shorter overall survival 
(OS) and progression free survival (PFS) in univariate analysis. Patients with SRSF2 
mutations were associated with better OS and PFS. Response rate was 55%; but we 
could not correlate the presence of TET2 and TP53 mutations with AZA response. 
Patients with sAML presented more variations than patients with high-risk MDS, and 
usually at relapse the number of mutations increased, supporting the idea that in 
advanced stages of the disease there is a greater genomic complexity. These results 
confirm that mutation analysis can add prognostic value to high-risk MDS and sAML 
patients, not only at diagnosis but also at follow-up.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are a group of 
myeloid neoplasms originated in hematopoietic stem cells, 
characterized by cytopenias, dysplasia in one or more cell 
lines, ineffective hematopoiesis and an increased risk of 
progression to secondary acute myeloid leukemia (sAML) 
[1, 2]. The outcome of MDS patients is extremely variable 
with median overall survival (OS) ranging from over 5 
years to less than 6 months [3]. 
Recurrent chromosomal aberrations have been 
linked with distinct outcomes and are one of the most 
important risk factors when patients are stratified 
according to their risk level before therapy. However, 
approximately 50% of patients with AML or MDS 
have a normal karyotype and lack recurrent cytogenetic 
abnormalities, which suggests the implication of other 
molecular events in the pathogenesis of these diseases [4]. 
Over the past decade, the application of new high-
throughput technologies to the study of MDS has led to 
the identification of several recurrently mutated genes 
in these disorders [5–7] and somatic gene mutations 
have been found to be more common than previously 
expected. The most common mutations found in MDS 
occur in genes involved in RNA splicing (including 
SF3B1, SRSF2, U2AF1 and ZRSR2) [8] and epigenetic 
regulators (including TET2, ASXL1 and DNMT3A) 
[9]. Several regulators of signal transduction (NRAS, 
JAK2) and transcription factors (RUNX1, TP53) are 
also frequently mutated in MDS. The complex patterns 
of associations between gene mutations have revealed 
epistatic interactions between spliceosome components 
and epigenetic modifiers in MDS [10]. 
Some of the mutated genes identified using these 
high-throughput techniques have been shown to provide 
important prognostic information. For example, mutations 
in ASXL1, TP53, EZH2, ETV6 and RUNX1 have been 
described to be predictors of poor OS in patients with MDS, 
independently of the already established risk factors [11]. 
This genetic variability together with the diversity 
in the clinical presentation of MDS, emphasizes the 
need for tailored treatment of patients. Current therapy 
options comprise supportive therapy, growth factor 
therapy, chemotherapy, immunotherapy, epigenetic 
therapy and allogeneic stem-cell transplantation (ASCT) 
[12, 13]. To date, ASCT is the only treatment considered 
as curative; however, due to high toxicity of the treatment 
and the advanced age of many MDS patients at diagnosis, 
it can only be applied on a limited subset of cases. 
Hypomethylating agents (HMAs) like 5-azacytidine 
(AZA) and decitabine have shown a high efficacy in 
MDS, especially in high-risk MDS patients, remaining the 
mainstay of treatment in this subtype of MDS, however 
only half of all patients will respond to these drugs 
[14–16]. The reasons underlying AZA resistance are 
unknown, and few alternatives exist for non-responders. 
Recently, it has been said that primary AZA resistance is 
intricately linked to cell cycle quiescence of hematopoietic 
progenitor cells (HPC) in non-responders before treatment, 
and AZA response is associated with the induction of an 
inflammatory response in HPCs in vivo [17]. Even so, 
there is a lack of biological markers that predict which 
patients will respond to HMAs, so more studies focusing 
in specific subtypes of MDS are needed. 
In this study, we performed a mutation analysis of 
83 genes involved in myeloid malignancies in a cohort 
of high-risk MDS and sAML patients treated uniformly 
with AZA according to a prospective multicenter protocol 
from the CETLAM Group. The aim of the study was to 
define the mutational status at diagnosis, to identify the 
relationship between genotype and treatment response, 
to establish if any gene mutation could be used as a 
prognostic marker for response and survival and to study 
the evolution of mutations during patients’ follow-up 
(response and relapse). 
RESULTS
Patient characteristics and treatment given
A total of 39 patients with high-risk MDS and 
sAML were studied. Main clinical and biological 
characteristics of patients are summarized in Table 1. 
Median age at diagnosis was 71 years (range 55-83) and 
the series included 29 (74%) males and 10 (26%) females. 
According to the 2008 WHO classification cases were 
diagnosed of refractory anemia with ring sideroblasts 
(RARS) (n = 1), refractory cytopenia with multilineage 
dysplasia and ring sideroblasts (RCMD-RS) (n = 1), 
refractory cytopenia with multilineage dysplasia (RCMD) 
(n = 5, 13%), refractory anemia with excess of blasts-1 
(RAEB-1) (n = 9, 23%), refractory anemia with excess 
of blasts-2 (RAEB-2) (n = 14, 36%) and sAML (n = 9, 
23%). Patients risk stratification was made according 
to the Revised International Prognostic Scoring System 
(IPSS-R) score and all patients belonged to intermediate, 
high or very high-risk groups (Table 1). All patients were 
treated with AZA (at a dose of 75 mg/m2/d for 7 days, 5-2-
2, every 4 weeks). The median number of AZA cycles was 
6 (range 1–36).
Conventional cytogenetics
An informative result for conventional cytogenetics 
(CC) studies at diagnosis was obtained in all patients. 
Eight (21%) patients had a normal karyotype or a loss 
of chromosome Y. The rest of patients (79%) had an 
abnormal karyotype, being in most of cases a complex 
karyotype.
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Table 1: Main clinical and hematological characteristics of high-risk MDS and sAML patients at diagnosis (n = 39)
Variable Median (range) N = 39 (%)
Age, years
<70 y
≥70 y
71 (55–83)
18 (46)
21 (54)
Gender
Male
Female
29 (74)
10 (26)
WHO classification
RARS
RCDM-RS
RCMD
RAEB-1
RAEB-2
sAML
1 (2.5)
1 (2.5)
5 (13)
9 (23)
14 (36)
9 (23)
Hemoglobin level, g/dL 
<10 g/dL
≥10 g/dL
9.1 (6.5–12.5) 29 (74)
10 (26)
Leukocyte count, × 109/L 
<4 × 109/L
>4 × 109/L and <11 × 109/L
≥11 × 109/L
2.9 (1.1–50.2)
29 (74)
8 (21)
2 (5)
Platelet count, × 109/L 
<100 × 109/L
≥100 × 109/L
63 (13–416)
28 (72)
11 (28)
Neutrophil count, × 109/L 
<0.8 × 109/L
≥0.8 × 109/L
1.3 (0.09–13.55)
13/36 (36)
23/36 (64)
Blasts in PB, % 
<5%
 ≥5%
0 (0–20)
32/38 (84)
6/38 (16)
Blasts in BM, % 
<20%
≥20%
11 (0–36)
29 (74)
10 (26)
Cytogenetics
Normal karyotype
Abnormal karyotype
8 (21)
31 (79)
IPSS risk group 
Intermediate-1
Intermediate-2
High
4 (10)
19 (49)
16 (41)
IPSS-R risk group 
Intermediate
High
Very High
5 (13)
12 (31)
22 (56)
BM: bone marrow; PB: peripheral blood; RAEB-1: refractory anemia with excess of blasts-1; RAEB-2: refractory anemia 
with excess of blasts-2; RARS: refractory anemia with ring sideroblasts; RCMD: refractory cytopenia with multilineage 
dysplasia. 
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Targeted deep sequencing
Targeted deep sequencing was performed in a 
total of 77 samples (39 at diagnosis, 17 follow-ups [6 at 
response and 11 at relapse] and 21 CD3+ control samples), 
with a mean depth per base per sample of 737-fold (range: 
84-971). More than 95% of the target sequences were 
analyzed with >100 independent reads and >99% with 
at least 30 reads. After applying the mentioned filters in 
methodology, a mean of 2 variants per sample were called 
as high-probability somatic changes (range 0-5). 
Mutational analysis at diagnosis
Across the entire cohort, 37/39 (95%) of patients 
harbored at least one mutation, affecting 35 of the 83 
studied genes (in 48 genes we did not find any mutation). 
Details of all the detected variants are described in 
Supplementary Table 2. Due to the availability of the 
CD3+ control tissue, we were able to discard a mean 
of 2 variants per sample that had not been previously 
established as SNPs in public databases. Overall, the 
distribution of the number of mutations detected per 
patients was as follows, 12 (31%) patients had 1 mutation, 
11 (28%) patients had 2 concurrent mutations, 2 (5%) 
patients had 3 mutations, 7 (18%) patients had 4 mutations 
and 5 (13%) patients had 5 mutations (Supplementary 
Figure 1A). The distribution of mutations at diagnosis 
across patients’ cohort is described in Figure 1. The most 
frequently affected genes (in >10% of patients) were TP53 
(49%), DNMT3A (21%) and SRSF2 (18%); followed by 
TET2 (15%) and U2AF1 (15%). The list of frequencies 
of all the affected genes is described in Supplementary 
Table 3, and most of detected mutations corresponded to 
missense variants (Supplementary Figure 1B).
Regarding cytological category, the average of 
alterations detected in each category is detailed in Table 
2, suggesting that patients with sAML present more 
variations than patients with RAEB-2, RAEB-1 or 
RCMD, even though this observation has to be taken with 
caution due to the number of patients in each category. 
We then examined the correlation between gene mutations 
Figure 1: Distribution of mutations detected at diagnosis (n = 39 patients).
Table 2: Average of mutations per cytological category
 Number of patients Average number of mutations per patient (range)
sAML 9 2.889 (1–5)
RAEB-2 14 2.286 (0–5)
RAEB-1 9 2 (1–4)
RCMD 5 2.2 (1–4)
RCMD-RS 1 5
RARS 1 1
RAEB-1: refractory anemia with excess of blasts-1; RAEB-2: refractory anemia with excess of blasts-2; RARS: refractory 
anemia with ring sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; RCMD-RS: refractory cytopenia 
with multilineage dysplasia and ring sideroblasts; sAML: secondary acute myeloid leukemia.
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to identify possible functional interactions across the 
different affected genes. Due to the heterogeneity of 
mutated genes in the cohort of patients, we focused the 
statistical analyses only in those mutations detected in 
at least five patients. The only association found was the 
correlation between SRSF2 and TET2 mutations (P = 
0.006), and both mutations were mutually exclusive with 
TP53 mutations (P = 0.008).
Relations between gene mutations and clinical 
variables
We investigated the relation between mutations 
detected at diagnosis and main clinical and biological 
parameters of the patients, including age, gender, WHO 
subtypes, peripheral blood cell counts, percentage of 
blasts in peripheral blood and bone marrow, karyotype and 
IPSS-R categories. We observed more SRSF2 mutations 
in patients with advanced age (>70 years), even though 
it wasn’t statistic significant (6 patients vs. 1 patient; P 
= 0.098), and these mutations were associated with the 
absence of a complex karyotype (P = 0.010). U2AF1 
mutations were associated with fewer neutrophils in 
peripheral blood (<0.8 × 109/L) (P = 0.003). Patients with 
TET2 wild-type were associated with less than 5% of 
blasts in peripheral blood (P = 0.021). Mutations in TP53 
gene were associated with age, younger than 70 years (P 
= 0.007), abnormal karyotype (P = 0.003), mainly with 
complex karyotype (P < 0.001), and with high-risk groups 
according to IPSS-R (P = 0.003). 
We also studied the effect of TP53 mutations in the 
subset of patients that underwent ASCT (n = 5); three of 
them harbored a TP53 mutation and died in less than one 
year from MDS diagnosis. The other two patients, without 
TP53 mutations, remain alive after more than 3 years after 
diagnosis.
Overall survival and progression free survival 
analysis
We then explored the impact of clinical and 
biological data on patients’ outcome. Median follow-up of 
alive patients was 11 months (range 0–68), and median OS 
and PFS (95% CI) of the cohort were 1.1 years (0.6, 1.6) 
and 0.9 years (0.8, 1), respectively. Complex karyotype, 
IPSS-R risk group and hemoglobin were predictive of 
both OS and PFS (Table 3). In addition, there was a trend 
to worse PFS in patients with more than 5% of blasts in 
peripheral blood at diagnosis. Regarding genetic features, 
we did not find any association between the number of 
mutations and OS or PFS. Focusing on specifics genes, 
only mutations in TP53 were associated with shorter OS 
and PFS, while mutations in SRSF2 correlated with better 
OS and PFS (Figure 2). Considering together SRSF2 and 
TP53 mutational status, patients could be stratified in 
three groups with significant different rates of OS and PFS 
(Figure 3).
Finally, we performed an adjusted multivariable Cox 
model including cytogenetic, IPSS-R and TP53 mutational 
status (Table 3). For both OS and PFS, TP53 mutational 
status was the only variable which remained significant.
Predicting factors of response to hypomethylating 
therapy 
In our cohort of patients, 16 cases were classified as 
responders (8 CR and 8 PR) to AZA at six months and 8 
cases were classified as non-responders (2 stable disease 
and 6 treatment failure). There were 15 patients who 
died before the sixth cycle, but from those patients who 
received a minimum of 3 cycles of AZA we assessed their 
response according to the percentage of blasts in bone 
marrow and their transfusion requirements during these 
months. Afterwards, we could incorporate into the analysis 
seven more patients, six as non-responders, because their 
transfusions requirements did not decrease or because the 
blasts percentage increased under AZA treatment, and one 
patient was considered a responder because his transfusion 
requirements decreased with AZA treatment before being 
allografted. The other 8 patients received less than 3 
AZA cycles and they were considered as no evaluable for 
response predicting factors. 
The overall response rate (ORR) for evaluable 
patients was 55% (17/31). Univariate analysis of the 
impact of clinical characteristics and mutational status 
on response rates are summarized in Table 4. We did not 
find any clinical variable or gene mutation associated with 
treatment response.
Mutational follow-up during response, relapse or 
AML progression 
Targeted deep sequencing was performed at response 
in six patients and at relapse or AML transformation in 
eleven patients (Table 5). In two patients the number of 
mutations at response decreased (patients ID32 and ID28), 
two patients maintained the number of mutations (patients 
ID13 and ID25) and in two more patients the number of 
mutations increased (patients ID7 and ID20), even though 
they had hematological improvement (Figure 4). The 
number of mutations detected per patient was the same 
between diagnosis and progression in 4/11 patients (ID4, 
ID16, ID23 and ID25) (36.4%) and increased at time of 
relapse or AML progression in 6/11 patients (ID7, ID11, 
ID13, ID20, ID28 and ID32) (54.5%). In patient ID32, 
the dominant clone observed at diagnosis disappeared 
in complete response but reappeared on relapse with 
mutations in other genes. Only one patient (ID21) did not 
present at relapse the mutation found at diagnosis or any 
other mutation from the studied gene panel.
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DISCUSSION
MDS is a heterogeneous disease, and so are the 
genetic alterations more appellants, as they include 
gains or losses of chromosomal regions, mutations and 
epigenetic modifications [18–20]. Over the past few 
years, next-generation sequencing (NGS) has led to a 
revolution in the study of hematological malignancies, 
with remarkable efforts to characterize the mutational 
basis of these disorders. Focusing on MDS, targeted deep-
sequencing has identified a landscape of mutated genes 
that encode signal transduction proteins (NRAS , FLT3-
ITD, CBL, JAK2, KIT), transcription factors (RUNX1, 
ETV6), tumor suppressors genes (TP53, WT1), epigenetic 
modifiers (TET2, ASXL1, IDH1, IDH2, EZH2, DNMT3A), 
RNA splicing machinery (SF3B1, U2AF1, SRSF2, ZRSR2) 
and components of the cohesin complex (STAG2, RAD21, 
SMC3, SMC1A) [10, 18, 21]. However, no mutations in 
these genes are detected in 10–20% of MDS patients. 
In our series, using a panel of 83 myeloid related genes, 
we were able to detect mutations in 95% of patients with 
high-risk MDS and sAML. This percentage is higher 
than other studies focused on MDS, maybe due to our 
patients are high-risk and this supports the idea that in 
advanced stages of the disease there is a greater genomic 
complexity. Only 5 genes (TP53, DNMT3A, SRSF2, TET2 
and U2AF1) were present in more than 10% of cases. We 
found mutations in 30 additional genes, but in a lower 
frequency (Figure 1) and no mutation was found in the rest 
of the studied genes (n = 48). These results corroborate 
the heterogeneous landscape of MDS at the mutational 
level. We would also like to emphasize, that many groups 
do not use control tissue when NGS is performed, may 
be due to the increase on cost that this implies, but we 
have demonstrated its usefulness to discriminate germ line 
variations from somatic mutations. In our study, due to the 
availability of the CD3+ control tissue, we have been able 
to discard a mean of two variables per sample that had not 
been established as SNPs in public databases. Otherwise 
it would have wrongly increased the number of mutations 
detected per patient.
In MDS the percentage of TP53 mutations is 
approximately 20% [13] but in our cohort this percentage 
increased up to nearly 50%. This fact could be explained 
because our cohort of patients include only high-risk 
MDS and sAML, which have been highly associated with 
complex karyotypes (46% in our series) and it is also well 
known that TP53 mutations are enriched in patients with 
these cytogenetic characteristics [22]. Another explanation 
could be that the limited number of patients included in 
our series have influenced this percentage. Recently, 
some studies have demonstrated the association between 
mutations in TP53 and higher response rate to high doses 
of decitabine in AML and MDS patients [23, 24]. Although 
AZA and decitabine are both HMAs, we could not 
corroborate these results in our cohort treated with AZA. 
Table 3: Results of overall survival and progression free survival univariate and multivariate analyses
UNIVARIATE ANALYSIS 
Variable Categories
Overall Survival (OS) Progression Free Survival (PFS)
Median OS 
(95% CI) P value
Median PFS 
(95% CI) P value
Karyotype
Normal 2.1 (1.2, 3)
0.022
1.75 (1.7, 1.8)
0.01
Altered 0.9 (0.7, 1) 0.8 (0.6, 1.1)
Hemoglobin 
level
<100 0.9 (0.5, 1.2)
0.028
0.8 (0.5, 1.1)
0.029
≥100 2.1 (0.6, 3.6) 1.7 (0.3, 3.1)
IPSS-R
Intermediate 2 (0, 4.6)
0.026
1.2 (0.2, 2.2)
0.005High 1.7 (1.2, 2.2) 1.7 (0.8, 2.7)
Very high 0.5 (0.1, 1) 0.5 (0.2, 0.8)
TP53
WT 1.7 (0.9, 2.6)
0.005
1.4 (0.6, 2.2)
0.002
Mutated 0.8 (0.2, 1.4) 0.7 (0.3, 1)
SRSF2
WT 0.9 (0.7, 1.2)
0.043
0.9 (0.7, 1)
0.007
Mutated 3.8 (1.5, 6.1) 3.7 (1.5, 5.9)
MULTIVARIATE ANALYSIS
Variable Baseline category
Overall Survival (OS)* Progression Free Survival (PFS)**
HR (95% CI) P value HR (95% CI) P value
TP53 WT 2.9 (1.3, 6.3) 0.007 3.4 (1.5, 7.5) 0.003
Oncotarget19348www.oncotarget.com
An explanation may be the different treatment schedules or 
doses used between the two drugs, as well as differences 
mechanisms of action of both treatments (incorporation 
into DNA of decitabine and incorporation into RNA and 
DNA of AZA) [25], or even though to specific disease 
characteristics of the patients treated within each study. 
Due to the large amount of genetic information 
currently available, some groups are working in 
incorporating molecular data into the IPSS-R in patients 
with MDS [26]. As TP53 mutations have recurrently been 
associated with decreased OS and higher rates of AML 
transformation [7, 11], it seems to be a good candidate for 
being incorporated to this score. We have also corroborated 
this finding in our study, as TP53 mutations were the only 
marker that retained its significance in the multivariate 
analysis for PFS and almost for OS. Mutations in TP53 
are also associated with poorer OS after ASCT [27, 28]. 
In accordance to these studies, and although in our series 
only 5 patients were allografted, the three patients who 
had TP53 mutations died in less than one year after the 
MDS diagnosis, whereas the two patients without TP53 
alterations are still alive after more than 3 years after 
diagnosis.
It is well established that spliceosome mutations, 
such as SRSF2, are mutually exclusive among them 
but they usually coexist with mutations in epigenetic 
modifiers, cooperating to give rise to the MDS phenotype 
[29]. In our cohort we also observed this association 
between SRSF2 and TET2. The role of SRSF2 mutations 
in MDS is not yet well understood; while in some studies, 
these mutations have been associated with worse OS 
and a higher rate of transformation to AML [30], other 
groups have demonstrated that SRSF2 mutations do not 
have impact on OS [31]. In our cohort, SRSF2 mutations 
was an independent variable for better OS and PFS in the 
univariate analysis and together with TP53 mutations it 
allows to stratify patients into three risk group categories 
(Figure 3). These results have to be taken with caution 
as in our series, SRSF2 mutations were associated with 
TET2 mutations (4/7) (which have been defined as a factor 
of response to HMAs [32] particularly when ASXL1 is 
not mutated) and none of these four patients had ASXL1 
mutations. Considering also the limited number of patients 
with SRSF2 mutations in our study, the good prognosis 
of SRSF2 mutations should be confirmed in a bigger 
independent cohort of high-risk MDS patients. 
Figure 2: (A) Overall survival and (B) Progression free survival according TP53 and SRSF2 mutational status.
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There are some studies that have shown a relationship 
between a higher number of oncogenic mutations with 
an adverse outcome [20]. In our cohort we could not 
demonstrate this relationship (data not shown) maybe due 
to the high proportion of patients with TP53 mutations, 
which by itself gives a worse outcome to the patient.
Even though there are some studies that correlate 
mutational status to treatment response [23, 24, 32] we 
could not demonstrate this impact in our cohort. This fact 
could be explained by the limited number of evaluable 
patients for treatment response or due to differences 
between the designs of the studies.
Regarding MDS architecture, it has been defined 
that most cases of MDS are clonally heterogeneous, 
with a founding clone and multiple additional subclones. 
Using targeted deep sequencing techniques, it has become 
possible to find driver mutations involved in clonal 
evolution of MDS [10, 20, 33]. Driver mutations are 
defined as mutations in an immature hematopoietic stem 
cell with capacity for self-renewal; typically involving a 
gene of RNA splicing or DNA methylation, that provides 
selective advantage and determines local clonal expansion 
[7, 20]. To elucidate differential roles of mutations in 
MDS, we investigated clonal dynamics using targeted 
deep sequencing in 11 patients. Most of the mutations that 
we found at diagnosis were in genes that control cell cycle 
(TP53), DNA methylation (DNMT3A) and spliceosome 
machinery (SRSF2). The mean number of gene mutations 
in a patient with MDS tends to be higher in the high-risk 
subtypes, supporting the idea that some MDS stem cells 
gain the ability to proliferate through the accumulation of 
gene mutations, leading to clonal expansion and disease 
progression [10]. At progression, most of patients from 
our cohort experienced an increase in the number of 
mutations, their diversity and clone sizes, with alterations 
frequently found in the dominant clones with or without 
their sweeping previous clones. It has been described 
that the emergence of new driver mutations, even if they 
are still subclonal, can have relevant implications for the 
future disease evolution. In our cohort we could observe 
two patients with an increase in the number of mutations 
despite having hematological improvement, and these 
patients progressed faster than the other ones. Studying 
mutation evolution during patient’s follow-up may allow 
to identify patients whose disease will progress faster, 
even before symptoms appear. 
In summary, although we are aware that, compared 
with other studies, our series is limited by the number of 
studied samples, we have one of the better well studied 
cohorts of a homogeneous subtype of MDS, in which 
DNA from CD3+ cells as control tissue was available 
to avoid germinal variables. Our findings corroborate 
the higher incidence of TP53 mutations among high-risk 
MDS, that molecular markers such as TP53 and SRSF2 
mutations provide additional prognostic data to guide 
clinical decisions in high-risk MDS and that the use of 
mutation analysis during follow up may help to identify 
patients who are progressing before the onset of signs of 
progression. All these facts emphasize the importance of 
introducing genetic data into prognostic models to better 
stratify patients at diagnosis. Nonetheless, future studies 
including larger cohorts of patients treated homogenously 
with AZA are needed to consolidate our results.
MATERIALS AND METHODS
Patients and samples
A total of 39 high-risk MDS (n = 30) and sAML 
(n = 9) patients, at diagnosis and after AZA treatment, 
were retrospectively analyzed in this study. Samples 
were collected from October 2009 to December 2014. 
Patients were diagnosed according to the 2008 World 
Health Organization (WHO) classification [34] in 
Figure 3: (A) Overall survival and (B) Progression free survival considering together TP53 and SRSF2 mutational status.
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Table 4: Differences in treatment response based on clinical characteristics and mutational status from 31 evaluable 
patients
Variable Non-respondersn = 14 (%)
Responders
n = 17(%)
p-value
Age, years
<70
≥70
5 (36)
9 (64)
8 (47)
9 (53)
0.524
Gender
Male
Female
9 (64)
5 (36)
14 (82)
3 (18)
0.412
WHO classification
RARS
RCDM-RS
RCMD
RAEB-1
RAEB-2
sAML
1 (7)
1 (7)
1 (7)
5 (36)
4 (29)
2 (14)
0
0
4 (24)
1 (6)
7 (41)
5 (29)
-
Hemoglobin level, g/dL 
<10 g/dL
≥10 g/dL
12 (86)
2 (14)
10 (59)
7 (41)
0.132
Leukocyte count, × 109/L 
<4 × 109/L
>4 × 109/L and <11 × 109/L
≥11 × 109/L
8 (57)
6 (43)
0
14 (82)
2 (12)
1 (6)
0.112
Platelet count, × 109/L 
<100 × 109/L
≥100 × 109/L
10 (71)
4 (29)
12 (71)
5 (29)
1
Neutrophil count, × 109/L 
<0.8 × 109/L
≥0.8 × 109/L
3 (23)
10 (77)
8 (47)
9 (53)
0.177
Blasts in PB, % 
<5%
 ≥5%
10 (71)
4 (29)
15 (94)
1 (6)
0.157
Blasts in BM, % 
<20%
≥20%
12 (86)
2 (14)
11 (65)
6 (35)
0.240
Cytogenetics
Normal karyotype
Abnormal karyotype
3 (21)
11 (79)
4 (24)
13 (76)
1
IPSS risk group 
Intermediate-1
Intermediate-2
High
2 (14)
7 (50)
5 (36)
2 (12)
7 (41)
8 (47)
0.816
IPSS-R risk group 
Intermediate
High
Very High
3 (21)
5 (36)
6 (43)
2 (12)
6 (35)
9 (53)
0.739
TP53 mutational status
Wild-type
Mutant
8 (57)
6 (43)
10 (59)
7 (41)
0.925
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DNMT3A mutational status
Wild-type
Mutant
11 (79)
3 (21)
12 (71)
5 (29)
0.698
SRSF2 mutational status
Wild-type
Mutant
11 (79)
3 (21)
14 (82)
3 (18)
1
TET2 mutational status
Wild-type
Mutant
11 (79)
3 (21)
15 (88)
2 (12)
0.636
U2AF1 mutational status
Wild-type
Mutant
14 (100)
0
14 (82)
3 (18)
0.232
BM: bone marrow; PB: peripheral blood; RAEB-1: refractory anemia with excess of blasts-1; RAEB-2: refractory anemia 
with excess of blasts-2; RARS: refractory anemia with ring sideroblasts; RCMD: refractory cytopenia with multilineage 
dysplasia; RCMD-RS: refractory cytopenia with multilineage dysplasia and ring sideroblasts; sAML: secondary acute 
myeloid leukemia.
Table 5: List of affected genes in MDS patients that were studied at diagnosis, response and/or at time of progression/
relapse (n = 11)
Data at diagnosis Data at response Data at progression/ relapse
Pt ID and 
DX Alteration VAF Time Alteration VAF Time Alteration VAF
Pt ID4 DNMT3A c.2347T>A 31%  *  6M DNMT3A c.2347T>A 47.1%
RAEB-1 EZH2 c.371T>A 37.6%  relapse EZH2 c.371T>A 42.5%
 TP53 c.745T>C 32.3%  TP53 c.745T>C 42.9%
 TP53 c.637G>A 35.3%     TP53 c.637G>A 47.2%
Pt ID16 TP53 c.713C>T 38.8%  6M TP53 c.713C>T 34%
RAEB-1 TP53 c.395T>C 34.7%    progression TP53 c.395T>C 34%
Pt ID7 EZH2 c.2077T>A 79.4% 3M EZH2 c.2077T>A 80.7% 6M EZH2 c.2077T>A 72.6%
RAEB-1   Partial response IDH1 c394G>A 27.4% progression IDH1 c394G>A 35.3%
Pt ID11 TP53 c.371_372insC 68.6% *  2M TP53 c.371_372insC 38.8%
RAEB-1   progression NF1 c.282_283insG 27%
Pt ID32 BCOR c.2076_2077insA 62.4% 12M BCOR c.2752G>A 51.2% 27M BCOR c.2076_2077insA 79.3%
RAEB-2 BCORL1 c.4134_4135insA 68.2% Complete U2AF1 c.101G>A 34.6% Relapse
BCORL1 
c.4134_4135insA 84.6%
 STAG2 c.3616_3617insCAAT 65.8% response  
STAG2 
c.3616_3617insCAAT 84.1%
 U2AF1 c.101G>A 39.7%  U2AF1 c.101G>A 46.8%
   GATA2 c.569_570insGCCC 24.1%
       NF1 c.1067T>C 42.6%
Pt ID21
TP53 c.743C>T 48.2%  *  
12M
0
RAEB-2 relapse
Pt ID13 0  24M 0  36M LUC7L2 c.1300A>C 38.9%
RAEB-2  response  progression TERT c.1234G>A 40.9%
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       TET2 c.5103G>A 37%
Pt ID20
0  
4M
ASXL1 
c.1926_1927insG 32.6%
12M
ASXL1 c.1926_1927insG 35.9%
RAEB-2 Partial response relapse
Pt ID23 RUNX1 c.485C>T 25.4%  *  6M RUNX1 c.485C>T 64.3%
RAEB-2 SF3B1 c.1998C>G 37.6%    Relapse SF3B1 c.1998C>G 43.1%
Pt ID25 DNMT3A c.2546delAG 31.13% 3M DNMT3A c.2546delAG 17.6% 12M DNMT3A c.2546delAG 25.3%
RCMD TP53 c.824C>T 24.08%
Complete
TP53 c.824C>T 6.6% relapse TP53 c.824C>T 9.6%
response
Pt ID28 DNMT3A c.2141G>C 42.8% 5M DNMT3A c.2141G>C 23.7% 12M DNMT3A c.2141G>C 33.5%
sAML NPM1 c.859_860insTCTG 28.6% Complete 
NPM1 
c.859_860insTCTG 5.25% relapse RAD21 c.199_200insA 6.8%
 RAD21 c.199_200insA 36.8% response RAD21 c.199_200insA 5.96% WT1 c.594G>T 10.1%
 WT1 c.594G>T 38.5%     SUZ12 c.103A>G 13.6%
DX: diagnosis; M: month; Pt: patient; RAEB-1: refractory anemia with excess of blasts-1; RAEB-2: refractory anemia with excess of blasts-2; RCMD: refractory cytopenia with multilineage dysplasia; 
sAML: secondary acute myeloid leukemia; VAF: Variant allele frequency.
*No data at that point.
Genes that differ from the affected at time of diagnosis are highlighted in bold.
Figure 4: Variant allele frequency evolution during disease follow-up in eleven patients treated with 5-azacytidine. 
In 5 patients (ID4, ID11, ID16, ID21 and ID23) samples were available at diagnosis (DX) and relapse/progression. In 6 patients (ID7, 
ID13, ID20, ID25, ID28 and ID32) samples were available at diagnosis, response and relapse/progression. In both cases different patterns 
can be seen: Model 1: The variant allele frequency (VAF) of mutations, or the number of mutations, decreases on response and increases 
at progression (patient ID4, ID11, ID13, ID23, ID 25, ID28 and ID32). Model 2: Mutation’s VAF, or the number of mutations, increases 
on response indicating the progression of the disease even though an improvement of hematological features (patient ID7 and ID20) or 
no change has been seen between diagnosis and progression (ID16). Model 3: Mutation’s VAF, or the number of mutations, decreases or 
disappears on disease progression indicating that the cause of progression is not due to the mutations found at diagnosis (patient ID21).
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different hospitals from the CETLAM Group, and were 
treated uniformly with AZA (75 mg/m2 per day for 7 
days, 5-2-2, every 4 weeks). All patients received AZA 
during their disease evolution and five patients were 
allografted after AZA treatment. Response to treatment 
was assessed using the International Working Group 
(IWG) Response Criteria [35]. Briefly, patients in a 
complete response (CR), partial response (PR), marrow 
CR (mCR) or hematologic improvement (HI) after six 
months of treatment were considered as “responders”, 
while patients who had stable disease, no response or 
disease progression were considered as “non-responders”. 
Study approval was obtained from Ethical Committee for 
Clinical Research from Hospital Germans Trias i Pujol. 
Informed consent was given by all patients, in accordance 
with the Declaration of Helsinki. 
Cytogenetics
Conventional G-banding cytogenetics was 
performed on bone marrow samples at diagnosis in 
each center and karyotypes were described according 
to the International System for Human Cytogenetic 
Nomenclature 2013 [36]. 
DNA samples
Samples were collected at diagnosis for all 39 
patients and at time of response and/or progression in 
11 patients, all these samples were sent to a reference 
laboratory. Whole bone marrow samples were used for the 
targeted deep sequencing analysis. In 21 out of 39 patients, 
peripheral CD3+ T lymphocytes were purified with 
immunomagnetic separation (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s 
recommendations and were used as control tissue to 
discriminate germ line variations from somatic mutations. 
Genomic DNA was extracted with QiaAmp DNA Blood 
Mini kit (Qiagen, Hilden, Germany) and quantified using 
Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, CA, 
USA).
Targeted deep sequencing
Targeted deep-sequencing of a panel of 83 
myeloid-related genes was performed in all samples 
(Supplementary Table 1). Indexed libraries were prepared 
with 1 μg of double strand genomic DNA using the Kapa 
Library Preparation Kit (Kapa Biosystems, MA, USA). 
Custom target capture enrichment using the SeqCap 
EZ capture chemistry (Nimblegen, Roche, Basel, 
Switzerland) was performed on pools of 8 libraries. 
Multiplexed captured libraries were sequenced on an 
Illumina MiSeq following a 150bp paired-end reads 
standard protocol. 
Targeted sequencing data analysis
Sequencing data were analyzed using the 
commercial softwares MiSeq Reporter and Variant 
Studio (Illumina, CA, USA). High-probability oncogenic 
mutations were called after eliminating sequencing and 
mapping errors and after discarding variants located 
in high variable regions, with low coverage (<20 reads 
of the variant) or with a variant allele frequency (VAF) 
<10% for single nucleotide variants (SNVs) and <15% for 
insertions and deletions (indels) to ensure they were not 
technical artefacts. VAF was calculated as the number of 
the variant reads divided by the total number of reads for 
that position. Single nucleotide polymorphisms (SNPs) 
described on human genetic variation databases were also 
excluded. 
The information obtained from patient-specific 
control tissue was also used to confirm SNPs filtering 
strategy when available. The remaining variants were 
considered as candidate somatic mutations, and were 
finally tagged as oncogenic, based on the information 
derived from the literature and/or on the information 
given by in silico predictors (data are available in SRA 
with SRP133179 reference). 
Statistical analysis
Baseline characteristics were described as frequency 
and percentage for categorical variables and median 
and range for quantitative variables. Comparisons of 
categorical variables between patient subsets were 
compared using χ2 or Fisher’s exact test, when appropriate, 
while median test was used to compare continuous 
variables. OS was defined as time from diagnosis to the 
last follow-up or death from any cause and progression 
free survival (PFS) as time from diagnosis to progression 
or death related to disease [35]. Patients who underwent 
an ASCT were censored at that time for OS and PFS 
analysis. Survival curves were performed using the 
Kaplan-Meier method and log-rank test was used for 
comparisons between groups. Multivariate analysis was 
performed using Cox proportional-hazards regression 
model, considering Wald Backward as selection method. 
Two-sided P values < 0.05 were considered as statistically 
significant. The statistical package SPSS, version 24.0 
(SPSS Inc., Chicago, IL, USA) was used for all analyses.
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